JPM 2023: Boston Scientific Sees Transformational Potential In PFA, BD Sticks To '2025' Investment Strategy
Also: Insulet and Tandem Address Unmet Need In Insulin Pumps
Executive Summary
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies; Some use the conference as a platform for major announcements while some just take the opportunity to explain their 2023 outlook to investors. Here are some of the highlights from the presentations on the third day of the meeting.
You may also be interested in...
News We’re Watching: Potential Shockwave Sale, Medtronic Layoffs, Warning Letter For Abbott
This week, the US FDA announced the Class I recall of Fresenisu Kabi’s Ivenix Infusion System. Also: Successful trial results from Boston Scientific, Ancora partners with Egnite, and trade groups object to the Environmental Protective Agency’s proposed rules on ethylene oxide.
Medtronic Earns CE Mark For Affera Ablation System, Touts New PFA Results
Results of the PULSED AF trial confirm that Medtronic’s PulseSelect pulsed field ablation is safe and effective for atrial fibrillation ablation. The company will likely incorporate PulseSelect into its Affera cardiac mapping and ablation system, which will soon be available in Europe.
Getting Personal With Boston Scientific's Global CMO Ken Stein: Taking The Long View To Innovate, Serve Patients
In this new series titled Getting Personal, we talk to new and veteran senior executives about their journeys to corporate leadership, their motivations, passions, and the peaks and valleys of running a medtech company. Medtech Insight talked with Ken Stein, Boston Scientific’s global chief medical officer about his own diagnosis with atrial fibrillation and advice for others living with the disease, innovative technologies in development at Boston Scientific, and some of his proudest and more challenging times on the job, as well as his advice for other physicians who are contemplating a move into the corporate world.